(Q42910003)

11 November 2017

title

In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes (English)

1 reference

11 November 2017

0 references

1 reference

1

Ulrike Nowak-Göttl

0 references

author name string

Kevin Dietrich

2

1 reference

11 November 2017

Daria Schaffranek

3

1 reference

11 November 2017

Noha Sharaf Eldin

4

1 reference

11 November 2017

Yutaka Yasui

5

1 reference

11 November 2017

Christof Geisen

6

1 reference

11 November 2017

Lesley G. Mitchell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20833980

11 July 2024

language of work or name

English

0 references

publication date

10 September 2010

1 reference

full work available at URL

11 November 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

https://ashpublications.org/blood/article-pdf/116/26/6101/1491084/zh805210006101.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20833980

http://www.bloodjournal.org/cgi/content/abstract/116/26/6101

11 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20833980

http://ashpublications.org/blood/article-pdf/116/26/6101/1491084/zh805210006101.pdf

11 July 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

11 July 2024

1 reference

11 November 2017

volume

116

1 reference

11 November 2017

issue

26

1 reference

11 November 2017

page(s)

6101-6105

1 reference

Medication use leading to emergency department visits for adverse drug events in older adults

11 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity

11 July 2024

2

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

11 July 2024

4

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy

11 July 2024

5

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

11 July 2024

6

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans

11 July 2024

7

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

11 July 2024

8

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Genetic determinants of response to warfarin during initial anticoagulation

11 July 2024

9

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.

11 July 2024

10

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

11 July 2024

11

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population

11 July 2024

12

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

11 July 2024

14

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

The largest prospective warfarin-treated cohort supports genetic forecasting

11 July 2024

15

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Antithrombotic therapy in children

11 July 2024

16

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Acenocoumarol therapy in pediatric patients

11 July 2024

17

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

11 July 2024

19

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study

11 July 2024

20

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis

11 July 2024

21

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

A cross-sectional study evaluating post-thrombotic syndrome in children

11 July 2024

22

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Genetic analysis of CYP2C9 polymorphism in a Japanese population

11 July 2024

23

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

11 July 2024

24

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

11 July 2024

25

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

11 July 2024

26

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations

11 July 2024

27

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

11 July 2024

28

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics

11 July 2024

29

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Association of warfarin dose with genes involved in its action and metabolism

11 July 2024

30

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

11 July 2024

31

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

11 July 2024

32

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

11 July 2024

33

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes

11 July 2024

34

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Establishing reference ranges of cord blood: point-of-care hemostatic function assessment in preterm and term neonates

11 July 2024

35

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.

11 July 2024

38

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.

11 July 2024

40

1 reference

https://api.crossref.org/works/10.1182/BLOOD-2010-05-283861

11 July 2024

Identifiers

1 reference

11 November 2017

1 reference